title: Sensitivity to temozolomide in brain tumor initiating cells.
abstract: Molecular alterations in glioblastoma have the potential to guide treatment. Here, we explore the relationship between temozolomide (TMZ) response and O(6)-methylguanine DNA methyltransferase (MGMT) status in brain tumor initiating cells (BTICs). Methylation, expression, and sensitivity were assessed in 20 lines; associations were evaluated by Fisher's exact test. Some BTICs were sensitive. Sensitivity to TMZ was only associated with protein expression (P = .001). There were atypical BTICs including TMZ-resistant lines in which the methylation-specific PCR reaction revealed both methylated and unmethylated bands. BTICs are not uniformly resistant to TMZ; some are sensitive. MGMT status does not predict TMZ response with high precision.
authors.affiliation: Department of Clinical Neurosciences, Foothills Medical Centre, 1403 29th St NW, Calgary, Alberta, Canada.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Blough
authors.forename: Morgan R
authors.initials: MR
authors.lastname: Westgate
authors.forename: Desiree
authors.initials: D
authors.lastname: Beauchamp
authors.forename: John J
authors.initials: JJ
authors.lastname: Kelly
authors.forename: Owen
authors.initials: O
authors.lastname: Stechishin
authors.forename: Andrea L
authors.initials: AL
authors.lastname: Ramirez
authors.forename: Samuel
authors.initials: S
authors.lastname: Weiss
authors.forename: J Gregory
authors.initials: JG
authors.lastname: Cairncross
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide
references.citation: Neuro Oncol. 2009 Aug;11(4):348-56
references.pmid: 19224763
references.citation: Science. 1992 Mar 27;255(5052):1707-10
references.pmid: 1553558
references.citation: Clin Cancer Res. 2004 Jun 1;10(11):3728-36
references.pmid: 15173079
references.citation: Stem Cells. 2009 Aug;27(8):1722-33
references.pmid: 19544433
references.citation: Brain Pathol. 2008 Oct;18(4):520-32
references.pmid: 18400046
references.citation: Nature. 2008 Oct 23;455(7216):1061-8
references.pmid: 18772890
references.citation: Glia. 2006 Dec;54(8):850-60
references.pmid: 16981197
references.citation: N Engl J Med. 2005 Mar 10;352(10):987-96
references.pmid: 15758009
references.citation: J Neurooncol. 2009 Mar;92(1):23-31
references.pmid: 19011762
references.citation: Oncogene. 2009 Apr 16;28(15):1807-11
references.pmid: 19287454
references.citation: Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6
references.pmid: 8790415
references.citation: Cancer Res. 2008 Jul 15;68(14):5706-15
references.pmid: 18632623
references.citation: N Engl J Med. 2005 Mar 10;352(10):997-1003
references.pmid: 15758010
references.citation: J Biol Chem. 1980 Nov 25;255(22):10569-71
references.pmid: 7000780
references.citation: Clin Cancer Res. 2009 Jul 15;15(14):4622-9
references.pmid: 19584161
references.citation: J Clin Oncol. 2007 Apr 20;25(12):1470-5
references.pmid: 17442989
references.citation: Nature. 2001 Nov 1;414(6859):105-11
references.pmid: 11689955
references.citation: J Clin Oncol. 2007 Jan 1;25(1):118-45
references.pmid: 17159189
references.citation: Cancer Res. 1997 Sep 1;57(17):3672-7
references.pmid: 9288770